Paper Details

  1. Home
  2. Paper Details

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

Author: ColdeweyR, DeicherH, PeestD, SchedelI, SchmollH J

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study compared two chemotherapy regimens (MP and VCMP) for treating 320 patients with multiple myeloma. Both regimens achieved similar remission rates (around 72%), but patients treated with MP had significantly longer survival compared to those treated with VCMP. After achieving remission, patients were randomly assigned to receive either continued chemotherapy or no further treatment. Patients who stopped treatment relapsed earlier, but there was no difference in resistance to initial treatment or survival between the groups. The study suggests that MP therapy may be a more effective treatment for multiple myeloma than VCMP, and that while continued chemotherapy may delay relapse, it does not seem to affect long-term survival.
Paper Details　
Original Abstract of the Article :
In a prospective multicenter trial, 320 untreated myeloma patients of stage II and III were randomized for remission induction into two groups receiving six monthly courses of either MP or VCMP treatment. Response rates were equal in both groups: 72% remission, 21% no change, 7% progress for patient...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0277-5379(88)90160-5

データ提供：米国国立医学図書館（NLM）

MP vs. VCMP for Multiple Myeloma: A Multicenter Trial Exploring Treatment Options

Multiple myeloma, a complex cancer affecting plasma cells, requires tailored treatment strategies. This multicenter trial delves into the effectiveness of two different chemotherapy regimens, MP and VCMP, for inducing remission in patients with multiple myeloma. The researchers sought to compare the response rates, survival outcomes, and potential side effects of these two treatment approaches. The study provides valuable insights for clinicians seeking to personalize treatment plans for patients with multiple myeloma.

MP Shows Promise in Long-Term Survival for Multiple Myeloma

The study found that both MP and VCMP had comparable remission induction rates, but MP treatment was associated with significantly longer survival. This finding suggests that MP may offer a more favorable long-term outcome for patients with multiple myeloma. The researchers also observed that maintenance therapy, even in the absence of chemotherapy, did not significantly affect the development of resistance or overall survival.

A More Promising Path for Multiple Myeloma Patients

This multicenter trial underscores the importance of considering individual patient factors and treatment response when determining the most effective chemotherapy regimen for multiple myeloma. The study provides valuable insights into the long-term benefits of MP treatment and the potential impact of maintenance therapy on survival outcomes.

Dr.Camel's Conclusion

The study's findings offer a beacon of hope for patients with multiple myeloma. MP treatment emerged as a potential key to improved long-term survival, much like a camel's endurance allows it to traverse vast desert landscapes. This study emphasizes the ongoing quest for more effective and personalized treatments in the fight against this complex disease.

Date :
  1. Date Completed 1988-10-03
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

3044800

DOI: Digital Object Identifier

10.1016/0277-5379(88)90160-5

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.